<DOC>
	<DOCNO>NCT02296684</DOCNO>
	<brief_summary>The goal trial test ability MK-3475 ( pembrolizumab ) improve locoregional recurrence distant metastatic rate high-risk patient locally advanced head neck squamous cell carcinoma ( HNSCCs ) treat current standard care surgical approach .</brief_summary>
	<brief_title>Immunotherapy With MK-3475 Surgically Resectable Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm stage III IV HNSCC oral cavity , hypopharynx , oropharynx , larynx ( exclude p16 HPVpositive oropharynx primary sinonasal primary ) . Measurable disease define lesion accurately measure least one dimension ( long diameter record ) &gt; 10 mm CT scan , &gt; 20 mm chest xray , &gt; 10 mm caliper clinical exam RECIST 1.1 . At least 18 year age . ECOG performance status ≤ 1 Normal bone marrow organ function define : Absolute neutrophil count ≥ 1,500/mcl Platelets ≥ 100,000/mcl Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 x IULN OR Direct bilirubin ≤ IULN patient total bilirubin &gt; 1.5 x IULN AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x IULN ( ≤ 5 x IULN patient liver metastasis ) Serum creatinine ≤ 1.5 x IULN OR Creatinine clearance CockcroftGault ≥ 60 mL/min/1.73 m2 patient creatinine level &gt; 1.5 x IULN INR ≤ 1.5 x IULN unless patient receive anticoagulant therapy long INR PTT within therapeutic range intend use anticoagulant aPTT ≤ 1.5 x IULN unless patient receive anticoagulant therapy long INR PTT within therapeutic range intend use anticoagulant Sexually active woman childbearing potential men must agree use 2 method contraception ( hormonal barrier method birth control , abstinence ) prior study entry , duration study participation , 120 day last dose MK3475 . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Ability understand willingness sign IRB approve write informed consent document ( legally authorize representative , applicable ) . Prior treatment head neck cancer . Patients HPVpositive p16positive oropharyngeal SCCA . Patients sinonasal SCCAs Patients metastatic SCCA neck disease unknown primary tumor site Prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . Received live vaccine within 30 day prior first dose MK3475 . A history malignancy ≤ 3 year previous exception previous head neck cancer treat surgery , basal cell squamous cell carcinoma skin treat local resection , carcinoma situ cervix . Note : patient synchronous head neck cancer primary exception criterion may qualify study . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose MK3475 . Currently receive investigational agent participate study investigational agent use investigational device within 4 week first dose MK3475 . A history allergic reaction attribute compound similar chemical biologic composition MK3475 agent use study . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , immunosuppression , autoimmune condition , underlie pulmonary disease , psychiatric illness/social situation would limit compliance study requirement . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid , immunosuppressive drug ) . Replacement therapy ( e.g. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . Has history ( noninfectious ) pneumonitis require steroid current pneumonitis . Pregnant and/or breastfeeding . Patient must negative serum urine pregnancy test within 72 hour study entry . Known history active TB ( bacillus tuberculosis ) . Known active hepatitis B ( e.g . HBsAg reactsive ) hepatitis C ( e.g . HCV RNA [ qualitative ] detect ) . Known history HIV ( HIV 1/2 antibody ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>